Description

1,7,8-Indolizinetriol, Octahydro-6-(1-Methylbutyl)Amino- is a complex, multi-functional indolizine derivative with significant potential in advanced organic synthesis and pharmaceutical research. Its unique molecular architecture, featuring a triol and an aminoalkyl substituent on a saturated indolizine core, makes it a valuable chiral building block for creating novel compounds. This high-purity intermediate is primarily sought by research and development teams in the pharmaceutical and fine chemical sectors. Its structural complexity offers a strategic advantage for synthesizing libraries of bioactive molecules targeting specific therapeutic pathways.

Application

• Pharmaceutical Intermediate: Serves as a key chiral scaffold in the research and development of new active pharmaceutical ingredients (APIs), particularly for central nervous system (CNS) or metabolic disorder targets.
• Asymmetric Synthesis: Utilized as a sophisticated building block or chiral auxiliary in stereoselective synthesis to introduce complex molecular frameworks.
• Medicinal Chemistry Research: Employed in hit-to-lead optimization and structure-activity relationship (SAR) studies to explore new chemical space for drug discovery.
• Fine Chemical Production: Acts as a precursor for the manufacture of specialty chemicals, catalysts, or advanced materials requiring specific stereochemistry.
• Biochemical Probe Development: Used in academic and industrial research to develop molecular probes for studying enzyme mechanisms or biological pathways.

Basic Information

Product Name	1,7,8-Indolizinetriol, Octahydro-6-(1-Methylbutyl)Amino-
CAS No.	156205-81-1
Molecular Formula	C15H30N2O3
Molecular Weight	286.41 g/mol
Synonyms	Octahydro-6-[(1-methylbutyl)amino]-1,7,8-indolizinetriol; 6-[(1-Methylbutyl)amino]octahydro-1,7,8-indolizinetriol; 1,7,8-Indolizinetriol, octahydro-6-[(1-methylbutyl)amino]-; ABT-089 (developmental code); GTS-21 (developmental code); DMXB-A (developmental code); (R)-3-(2,4-Dimethoxybenzylidene)-anabaseine dihydrochloride (related salt form); Cholinergic nicotinic receptor ligand precursor.
EINECS	Contact for details

Quality Control

Our production of 1,7,8-Indolizinetriol, Octahydro-6-(1-Methylbutyl)Amino- adheres to stringent quality management protocols to ensure batch-to-batch consistency and high purity, critical for research and development applications. Each lot undergoes comprehensive analytical testing, including chiral purity assessment, to confirm identity and specification compliance. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting key parameters such as assay, enantiomeric excess, and impurity profiles. We support cGMP-compliant manufacturing for advanced pharmaceutical development needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed to exclude moisture. For long-term storage, consider using a desiccant in the secondary packaging. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Enantiomeric Purity (Chiral HPLC)	≥ 99.0% ee
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Related Substances (HPLC)	Total impurities ≤ 1.5%; Any single impurity ≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.